icon-folder.gif   Conference Reports for NATAP  
 
  The International Liver Congress™
EASL - European Association for the
Study of the Liver
2019 April 10-14
Vienna Austria
Back grey_arrow_rt.gif
 
 
 
In vitro and in vivo antiviral characterization of RO7049389, a novel small molecule capsid assembly modulator, for the treatment of chronic hepatitis B
 
 
  EASL 2018
Reported by Jules Levin
 
Xue Zhou1, Yuan Zhou1, Xiaojun Tian1, Fang Shen1, Guang Yang1, Wei Zhu1, Giorgio Ottaviani2, Jianxun Xie1, Hong Shen1, John A. T. Young2, and Lu Gao1
 
RO7049389, a core protein allosteric modulator, demonstrates robust anti-HBV activity in chronic hepatitis B patients and is safe and well tolerated - (04/18/18)
 
Combination treatment of a TLR7 agonist RO7020531 and a core protein allosteric modulator RO7049389 achieved sustainable viral load suppression and HBsAgloss in an AAV-HBV mouse model - (04/18/18)
 
HBV at EASL

0605191

0605192

0605193

0605194

0605195

0605196